Clinical Results of Cataract Surgery Using the ARTIS ® PL E Intraocular Lens

Purpose@#To compare the clinical outcomes of cataract surgery using the ARTIS ® PL E (Cristalens Industrie, Lannion, France) intraocular lens (IOL) and conventional Tecnis ® ZCB00 (Johnson & Johnson Vision, Santa Ana, CA, USA) IOL. @*Methods@#This retrospective study examined patients who underwent in-the-bag implantation of either an ARTIS ® PL E (33 eyes, group A) or Tecnis ® ZCB00 (45 eyes, group B) IOL after phacoemulsification performed by a single surgeon. Best-corrected visual acuity (BCVA), spherical equivalent, and higher-order aberrations (HOA) were measured 1 and 3 months after cataract surgery. @*Results@#Preoperative BCVA did not differ significantly in groups A and B. Postoperative BCVA at 1 and 3 months improved significantly (p < 0.001) in both groups compared to preoperative baseline BCVA. At 1 and 3 months postoperatively, total HOA, spherical aberration, and coma were significantly lower compared to the preoperative baseline HOA (p < 0.05) in both groups. However, there were no significant differences in the trefoil values 1 and 3 months postoperatively compared to the preoperative baseline in both groups. The absolute refractive error 3 months postoperatively was 0.27 ± 0.20 (group A) and 0.28 ± 0.20 (group B), both within ± 0.50 diopters of the targeted goal diopter; there were no significant differences in the accuracy or predictability of the IOL power calculation in both groups (p = 0.390, p = 0.959). The absolute refractive error 1 and 3 months postoperatively did not differ significantly; there were no significant differences in the stability of both IOLs (p = 0.482, p = 0.372). @*Conclusions@#Conventional cataract surgery using the ARTIS ® PL E IOL significantly increased the BCVA, while obtaining comparable clinical results to the verified Tecnis ® ZCB00 IOL in postoperative visual acuity and HOA.

Comparing Clinical Results after Intraocular Lens Implantation Surgery Using Three Other Aspheric Lenses

PURPOSE: We compared the clinical results after implantation of the newly-developed aspheric intraocular lens iSert 250 NC60 (Hoya Corporation Ltd., Tokyo, Japan) with 2 other types of widely used intraocular lenses, AcrySof IQ SN60WF (Alcon Laboratories, INC., Fort Worth, TX, USA) and TECNIS 1-piece ZCB00 (AMO Inc., Santa Ana, CA, USA). METHODS: Seventy cataract eyes were implanted with 1 of 3 aspheric intraocular lenses (Hoya iSert 250 NC60, TECNIS 1-piece ZCB00 or AcrySof IQ SN60WF) by the same surgeon. Uncorrected vision, best corrected vision, spherical equivalent, higher order aberrations, and modulation transfer function were measured 1 and 3 months after the cataract surgery. RESULTS: Uncorrected vision and best corrected vision were not significantly different among the 3 groups; however, eyes implanted with iSert250 NC60 showed more hyperopic-shifted postoperative spherical equivalents than expected compared to the other 2 groups. Total ocular aberrations and internal optics aberrations were similar among the 3 groups while the root mean square of the corneal aberrations showed differences. Eyes implanted with iSert 250 NC60 showed superior results in modulation transfer function compared with the other 2 groups in a majority of spatial frequencies 3 months postoperatively. CONCLUSIONS: The newly developed aspheric intraocular lens iSert 250 NC60 showed clinically equal results compared with 2 other verified intraocular lenses AcrySof IQ SN60WF and TECNIS 1-piece ZCB00 in vision, higher-order aberrations, and modulation transfer functions.

The Effects of Two Non-Steroidal Anti-Inflammatory Drugs, Bromfenac 0.1% and Ketorolac 0.45%, on Cataract Surgery

PURPOSE: To compare the additive effects of two types of non-steroidal anti-inflammatory drugs (NSAIDs), bromfenac 0.1% or ketorolac 0.45%, relative to topical steroid alone in cataract surgery. MATERIALS AND METHODS: A total 91 subjects scheduled to undergo cataract operation were randomized into three groups: Group 1, pre/postoperative bromfenac 0.1%; Group 2, pre/postoperative preservative-free ketorolac 0.45%; and Group 3, postoperative steroid only, as a control. Outcome measures included intraoperative change in pupil size, postoperative anterior chamber inflammation control, change in macular thickness and volume, and ocular surface status after operation. RESULTS: Both NSAID groups had smaller intraoperative pupil diameter changes compared to the control group (p<0.05). There was significantly less ocular inflammation 1 week and 1 month postoperatively in both NSAID groups than the control group. The changes in central foveal subfield thickness measured before the operation and at postoperative 1 month were 4.30+/-4.25, 4.87+/-6.03, and 12.47+/-12.24 microm in groups 1 to 3, respectively. In the control group, macular thickness and volume increased more in patients with diabetes mellitus (DM), compared to those without DM. In contrast, in both NSAID groups, NSAIDs significantly reduced macular changes in subgroups of patients with or without DM. Although three ocular surface parameters were worse in group 1 than in group 2, these differences were not significant. CONCLUSION: Adding preoperative and postoperative bromfenac 0.1% or ketorolac 0.45% to topical steroid can reduce intraoperative miosis, postoperative inflammation, and macular changes more effectively than postoperative steroid alone.

Modified free wrap-around flap for thumb reconstruction

No abstract available.